詹思延

个人简介  

北京医科大学医学学士和硕士,香港中文大学博士。
北京大学循证医学中心副主任,公共卫生学院流行病与卫生统计学系副主任,教授,博士生导师。
中国医师协会循证医学专业委员会主任委员,中华预防医学会流行病学分会常委、中华预防医学会循证预防医学专业委员会副主任委员、中国药学会药物流行病学分会委员。
《中华流行病学杂志》、《药物流行病学杂志》副总编,多家杂志的编委。主编《循证医学与循证保健》,主译《循证医学教学与实践》、《药物流行病学教程》,担任卫生部规划教材预防医学类专业《流行病学》第七版主编,八年制教材《循证医学》和《临床流行病学》的副主编。

研究领域

药物流行病学、循证医学

代表性科研项目(5项)

1. 中国结核病防治规划抗结核病药品不良反应研究 2007-2009,全球基金项目,负责人

2. 药物代谢酶基因多态性与抗结核药物致肝损害发生的遗传易感性研究,2008-2010,国家自然基金面上项目,负责人

3. 抗结核药物性肝损害的基因组流行病学研究,2011-2013,北京市自然基金重点项目,负责人

4. 诊断试验系统综述中识别和处理方法学异质性的研究,2013-2015,教育部博士点基金项目,负责人

5. 美兆自动化健检数据分析,2007-2009 美兆集团公司,负责人

发表的论文(10篇)

1. S Zhan, SC Ho. Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am J Clin Nutr 2005; 81(2):397-408.

2. S Zhan, SC Ho. Meta-analysis of the association of the Trp64Arg polymorphism in the beta3 adrenergic receptor with insulin resistance. Obes Res 2005; 13(10):1709-19.

3. P Shang, Y Xia, F Liu, X Wang, Y Yuan, D Hu, D Tu, Y Chen, P Deng, S Cheng, L Zhou, Y Ma, L Zhu, W Gao, H Wang, D Chen, L Yang, P He, S Wu, S Tang, X Lv, Z Shu, Y Zhang, Z Yang, Y Chen, N Li, F Sun, X Li, Y He, P Garner, S Zhan. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS One 2011; 6(7):e21836. (SCI IF=4.411)

4. F Sun, Y Chen, Y Xiang, S Zhan. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 2008; 12(9):994-1002.

5. F Sun, Q Tao, S Zhan. An accurate risk score for estimation 5-year risk of type 2 diabetes based on a health screening population in Taiwan. Diabetes Res Clin Pract 2009; 85(2):228-34.

6. F Sun, Q Tao, S Zhan. Metabolic syndrome and the development of chronic kidney disease among 118 924 non-diabetic Taiwanese in a retrospective cohort. Nephrology (Carlton) 2010; 15(1):84-92.

7. Xinghua Yang,Qiushan Tao,Feng Sun,Siyan Zhan. The impact of socioeconomic status on the incidence of metabolic syndrome in a Taiwanese health screening population. Int J Public Health,2012;57:551-559.(SCI IF=2.539)

8. Shanshan Wu, Yinyin Xia, Xiaozhen Lv, Yuan Zhang, Shaowen Tang, Zhirong Yang,Dehua Tu, Peiyuan Deng, Shiming Cheng, Xiaomeng Wang, Yanli Yuan, Feiying Liu, Daiyu Hu, Siyan Zhan. Effect of scheduled monitoring of liver function during anti-Tuberculosis treatment in a retrospective cohort in China. BMC Public Health. 2012 Jun 19, 12(1):454. (SCI IF=2.0)

9. Xiaozhen Lv, Shaowen Tang, Yinyin Xia, Yuan Zhang, Shanshan Wu, Zhirong Yang, Xiaoting Li, Dehua Tu, Yixin Chen, Peiyuan Deng, Yu Ma, Dafang Chen, Ru Chen, Siyan Zhan. NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population. Annals of Hepatology. 2012, 11(5):700-7. (SCI IF 1.811)

10. Feng Sun, Kai Yu, Zhirong Yang, Shanshan Wu, Yuan Zhang, Luwen Shi, Linong Ji, Siyan Zhan. Cardiovascular safety and glycemic control of Glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis. Diabetes Research and Clinical Practice 2012;98:386-395 (SCI IF=2.754)